You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 4, 2024

CEFIXIME Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


DrugPatentWatch® Litigation and Generic Entry Outlook for Cefixime

A generic version of CEFIXIME was approved as cefixime by AUROBINDO PHARMA LTD on April 14th, 2015.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for CEFIXIME?
  • What are the global sales for CEFIXIME?
  • What is Average Wholesale Price for CEFIXIME?
Summary for CEFIXIME
Drug patent expirations by year for CEFIXIME
Drug Prices for CEFIXIME

See drug prices for CEFIXIME

Recent Clinical Trials for CEFIXIME

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of North Carolina, Chapel HillPhase 2
Haiphong University of Medicine and PharmacyPhase 2
Universidad Peruana Cayetano HerediaPhase 3

See all CEFIXIME clinical trials

Pharmacology for CEFIXIME
Medical Subject Heading (MeSH) Categories for CEFIXIME
Paragraph IV (Patent) Challenges for CEFIXIME
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
SUPRAX for Oral Suspension cefixime 500 mg/5 mL 202091 1 2016-07-22

US Patents and Regulatory Information for CEFIXIME

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alkem Labs Ltd CEFIXIME cefixime CAPSULE;ORAL 210574-001 Oct 9, 2018 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Belcher CEFIXIME cefixime FOR SUSPENSION;ORAL 206938-002 Feb 6, 2017 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Aurobindo Pharma Ltd CEFIXIME cefixime FOR SUSPENSION;ORAL 204835-001 Apr 14, 2015 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Belcher CEFIXIME cefixime FOR SUSPENSION;ORAL 206939-001 Feb 6, 2017 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.